IVERIC bio Inc

NASDAQ:ISEE  
10.99
+0.15 (+1.38%)
Regulatory, Earnings Announcements

Iveric Bio Reports First Quarter 2022 Financial Results

Published: 05/04/2022 12:37 GMT
IVERIC bio Inc (ISEE) - Iveric Bio Reports First Quarter 2022 Operational Highlights and Financial Results.
Qtrly Loss per Share $0.29.
Q1 Earnings per Share View $-0.29 -- Refinitiv Ibes Data (analyst estimates).
Estimates Its Year-end 2022 Cash, Cash Equivalents and Available-for-sale Securities to Range Between $215 and $225 Million.
As of March 31, 2022, Company Had Approximately $345.7 Million in Cash, Cash Equivalents and Available-for-sale Securities.
Plans to Initiate a Clinical Trial Studying Zimura in Patients With Intermediate Amd in Q4 of 2022.
Expects to Submit an Investigational New Drug Application (ind) to FDA for Ic-500 During Mid-2023.
Iveric Bio-sees That Cash, Cash Equivalents & Available-for-sale Securities to Be Sufficient to Fund Requirements & Operating Expenses Through Mid-2024.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.30

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.33

More details on our Analysts Page.